@article{JGO21938,
author = {Kei Moriya and Tadashi Namisaki and Shinya Sato and Akitoshi Douhara and Masanori Furukawa and Hideto Kawaratani and Kosuke Kaji and Mitsuteru Kitade and Naotaka Shimozato and Yasuhiko Sawada and Kenichiro Seki and Soichiro Saikawa and Hiroaki Takaya and Takemi Akahane and Akira Mitoro and Yasushi Okura and Junichi Yamao and Hitoshi Yoshiji},
title = {Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {4},
year = {2018},
keywords = {},
abstract = {Background: Even though the Barcelona Clinic Liver Cancer (BCLC) staging system is widely accepted, controversies on the management of hepatocellular carcinoma (HCC) still exist. We evaluated the efficacy of an approach with repeated hepatic arterial infusion chemotherapy (HAIC) given at eight-week intervals for the treatment of advanced HCC.
Methods: Of the 66 compensated cirrhotic patients with advanced HCC refractory to transcatheter arterial chemo-embolization (TACE) enrolled in our study, 21 were treated by bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) and the rest by sorafenib. The overall survival periods, curative responses, and adverse events in each group were retrospectively analyzed.
Results: The efficacy rate was significantly higher in the B-HAIC group (38%, 11%, P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/21938}
}